- Name of the medicinal product
Lidocaine Hydrochloride injection 1% (2ml, 5ml, 30ml, 50ml) Taj Pharma
Lidocaine Hydrochloride injection 2%. (2ml, 5ml, 20ml, 50ml) Taj Pharma
- Qualitative and quantitative composition
a) Lidocaine Hydrochloride injection 1%
Lidocaine Hydrochloride 10mg
Sodium Chloride 7mg
NaoH/HCL for pH adjustment.
b) Lidocaine Hydrochloride injection 2%
Each ml contains:
Lidocaine Hydrochloride 20mg
Sodium Chloride 7mg
NaoH/HCL for pH adjustment.
For the full list of excipients, see section 6.1
- Pharmaceutical form
Solution for Injection
- Clinical particulars
4.1 Therapeutic indications
Lidocaine is a local anaesthetic of the amide group. The injectable form has a wide range of applications for nerve blockade. It can be used by percutaneous infiltration; to block a major nerve plexus such as the brachial; for epidural anaesthesia; for intravenous regional analgesia.
4.2 Posology and method of administration
The dosage should be adjusted according to the response of the patient and the site of administration. The lowest concentration and smallest dose producing the required effect should be given. The maximum dose for healthy adults should not exceed 200mg.
Children and elderly or debilitated patients require smaller doses, commensurate with age and physical status.
4.3 Contraindications
Hypersensitivity to the active substance, to anaesthetics of the amide type or to any of the excipients listed in section 6.1.
Lidocaine is contraindicated in patients with:
– Complete heart block
– Hypovolaemia
4.4 Special warnings and precautions for use
Lidocaine should be administered by persons with resuscitative skills and equipment. Facilities for resuscitation should be available when administering local anaesthetics.
It should be used with caution in patients with myasthenia gravis, epilepsy, congestive heart failure, bradycardia or respiratory depression, including where agents are known to interact with Lidocaine either to increase its availability or additive effects e.g. phenytoin or prolong its elimination e.g. hepatic or end renal insufficiency where the metabolites of Lidocaine may accumulate.
Intramuscular Lidocaine may increase creatinine phosphokinase concentrations which can interfere with the diagnosis of acute myocardial infarction. Lidocaine has been shown to be porphyrinogenic in animals and should be avoided in persons suffering from porphyria.
The effect of Lidocaine may be reduced if it is injected into inflamed or infected areas.
Hypokalaemia, hypoxia and disorder of acid-base balance should be corrected before treatment with intravenous lidocaine begins.
Certain local anaesthetic procedures may be associated with serious adverse reactions, regardless of local anaesthetic drug used.
Central nerve blocks may cause cardiovascular depression, especially in the presence of hypovolaemia, and therefore epidural anaesthesia should be used with caution in patients with impaired cardiovascular function.
Epidural anaesthesia may lead to hypotension and bradycardia. This risk can be reduced by preloading the circulation with crystalloidal or colloidal solutions. Hypotension should be treated promptly.
Paracervical block can sometimes cause foetal bradycardia or tachycardia and careful monitoring of the foetal heart rate is necessary (see section 4.6).
Injections in the head and neck regions may be made inadvertently into an artery causing cerebral symptoms even at low doses.
Retrobulbar injections may rarely reach the cranial subarachnoid space, causing serious/severe reactions including cardiovascular collapse, apnoea, convulsions and temporary blindness.
Retro- and peribulbar injections of local anaesthetics carry a low risk of persistent ocular motor dysfunction. The primary causes include trauma and/or local toxic effects on muscles and/or nerves.
The severity of such tissue reactions is related to the degree of trauma, the concentration of the local anaesthetic and the duration of exposure of the tissue to local anaesthetic. For this reason, as with all local anaesthetic, the lowest effective concentration and dose of local anaesthetic should be used.
Paediatric population
Lidocaine Injection is not recommended for use in neonates. The optimum serum concentration of lidocaine required to avoid toxicity, such as convulsions and cardiac arrhythmias, in this age group is not known.
4.5 Interaction with other medicinal products and other forms of interaction
Lidocaine toxicity is enhanced, by the co-administration of cimetidine and propranolol requiring a reduction in the dosage of lidocaine. Both drugs decrease hepatic blood flow. Also, cimetidine depresses microsomial activity. Ranitidine produces a small reduction in Lidocaine clearance. Increase in serum levels of lidocaine may also occur with anti-viral agents (e.g. amprenavir, atazanavir, darunavir, lopinavir).
Hypokalaemia caused by diuretics may antagonize the action of lidocaine if administered concomitantly (see section 4.4).
Lidocaine should be used with caution in patients receiving other local anaesthetics or agents structurally related to amide-type local anaesthetics (e.g. anti-arrhythmics, such as mexiletine), since the systemic toxic effects are additive. Specific interaction studies with lidocaine and class III anti-arrhythmic drugs (e.g. amiodarone) have not been performed, but caution is advised.
There may be an increased risk of ventricular arrhythmia in patients treated concurrently with antipsychotics which prolong or may prolong the QT interval (e.g. pimozide, sertindole, olanzapine, quetiapine, zotepine), prenylamine, adrenaline (if accidently injected intravenously)) or 5HT3 antagonists (e.g. tropisetron, dolasetron).
Concomitant use of quinupristin/dalfopristin may increase lidocaine levels with a subsequent increased risk of ventricular arrhythmias and therefore should be avoided.
There may be an increased risk of enhanced and prolonged neuromuscular blockade in patients treated concurrently with muscle relaxants (e.g. suxamethonium).
Cardiovascular collapse has been reported following the use of bupivacaine in patients on treatment with verapamil and timolol; Lidocaine is closely related to bupivacaine.
Dopamine and 5 hydroxytryptamine reduce the convulsant threshold to Lidocaine.
Narcotics are probably proconvulsants and this would support the evidence that Lidocaine reduces the seizure threshold to fentanyl in man.
Opioid-antiemetic combination sometimes used for sedation in children could reduce the convulsant threshold to Lidocaine and increase the CNS depressant effect.
While adrenaline when used in conjunction with Lidocaine might decrease vascular absorption, it greatly increase the danger of ventricular tachycardia and fibrillation if accidentally injected intravenously.
4.6 Pregnancy and lactation
Pregnancy
Although animal studies have revealed no evidence of harm to the foetus, lidocaine should not be administered during early pregnancy unless the benefits are considered to outweigh the risks.
Lidocaine readily crosses the placental barrier after epidural or intravenous administration to the mother. The ratio of umbilical to maternal venous concentration is 0.5 to 0.6. The foetus appears to be capable of metabolising Lidocaine at term. The elimination half life in the newborn of the drug received in utero is about three hours, compared with 100 minutes in the adult. Elevated lidocaine levels may persist in the newborn for at least 48 hours after delivery. Foetal bradycardia or tachycardia (see section 4.4), neonatal bradycardia, hypotonia or respiratory depression may occur.
Breast-feeding
Small amounts of Lidocaine are secreted into breast milk and the possibility of an allergic reaction in the infant, albeit remote, should be borne in mind when using lidocaine in nursing mothers.
4.7 Effects on ability to drive and use machines
Where major motor nerve block occurs e.g. Brachial plexus, epidural, spinal block. Where there is a loss of sensation resulting from nerve block to areas of muscle co-ordination or balance. Advice is that for general anaesthesia as sedative/hypnotic drugs are often used during nerve blockade.
4.8 Undesirable effects
In common with other local anaesthetics, adverse reactions to Lidocaine are rare and are usually the result of raised plasma concentrations due to accidental intravascular injection, excessive dosage or rapid absorption from highly vascular areas, or may result from a hypersensitivity, idiosyncrasy or diminished tolerance on the part of the patient. Systemic toxicity mainly involves the central nervous system and/or the cardiovascular system (see also 4.9 Overdose).
The undesirable effects are listed according to the frequency: Not known (cannot be estimated from the available data).
Immune system disorders
Hypersensitivity reactions (allergic or anaphylactoid reactions, anaphylactic shock) – see also Skin & subcutaneous tissue disorders).
Skin testing for allergy to Lidocaine is not considered to be reliable.
Nervous & Psychiatric disorders
Neurological signs of systemic toxicity include dizziness or light-headedness, nervousness, tremor, circumoral paraesthesia, tongue numbness, drowsiness, convulsions, coma.
Nervous system reactions may be excitatory and or depressant. Signs of CNS stimulation may be brief, or may not occur at all, so that the first signs of toxicity may be confusion and drowsiness, followed by coma and respiratory failure.
Neurological complications of spinal anaesthesia include transient neurological symptoms such as pain of the lower back, buttock and legs. These symptoms usually develop within twenty-four hours of anaesthesia and resolve within a few days. Isolated cases of arachnoiditis or cauda equina syndrome, with persistent paraesthesia, bowel and urinary dysfunction, or lower limb paralysis have been reported following spinal anaesthesia with lidocaine and other similar agents. The majority of cases have been associated with hyperbaric concentrations of Lidocaine or prolonged spinal infusion.
Blood and Lymphatic System Disorders
Lidocaine may also result in methaemoglobinaemia.
Eye disorders
Blurred vision, diplopia and transient amaurosis may be signs of lidocaine toxicity.
Bilateral amaurosis may also be a consequence of accidental injection of the optic nerve sheath during ocular procedures. Orbital inflammation and diplopia have been reported following retro or peribulbar anaesthesia (see section 4.4 Special warnings and precautions for use)
Ear and labyrinth disorders
Tinnitus, hyperacusis.
Cardiac and vascular disorders
Cardiovascular reactions are depressant and may manifest as hypotension, bradycardia, myocardial depression, cardiac arrhythmias and possibly cardiac arrest or circulatory collapse.
Hypotension may accompany spinal and epidural anesthesia. Isolated cases of bradycardia and cardiac arrest have also been reported.
Respiratory, thoracic or mediastinal disorders
Dyspnoea, bronchospasm, respiratory depression, respiratory arrest.
Gastrointestinal disorders
Nausea, vomiting.
Skin & subcutaneous tissue disorders
Rash, urticaria, angioedema, face oedema.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important.
By reporting side effects you can help provide more information on the safety of this medicine.
4.9 Overdose
Symptoms of acute systemic toxicity
Central nervous system toxicity presents with symptoms of increasing severity. Patients may present initially with circumoral paraesthesia, numbness of the tongue, light-headedness, hyperacusis and tinnitus. Visual disturbance and muscular tremors or muscle twitching are more serious and precede the onset of generalised convulsions. These signs must not be mistaken for neurotic behaviour. Unconsciousness and grand mal convulsions may follow, which may last from a few seconds to several minutes. Hypoxia and hypercapnia occur rapidly following convulsions due to increased muscular activity, together with the interference with normal respiration and loss of the airway. In severe cases, apnoea may occur. Acidosis increases the toxic effects of local anaesthetics.
Effects on the cardiovascular system may be seen in severe cases. Hypotension, bradycardia, arrhythmia and cardiac arrest may occur as a result of high systemic concentrations, with potentially fatal outcome.
Recovery occurs as a consequence of redistribution of the local anaesthetic drug from the central nervous system and metabolism and may be rapid unless large amounts of the drug have been injected.
Treatment of acute toxicity
If signs of acute systemic toxicity appear, injection of the anaesthetic should be stopped immediately.
Treatment will be required if convulsions and CNS depression occurs. The objectives of treatment are to maintain oxygenation, stop the convulsions and support the circulation. A patent airway should be established and oxygen should be administered, together with assisted ventilation (mask and bag) if necessary. The circulation should be maintained with infusions of plasma or intravenous fluids. Where further supportive treatment of circulatory depression is required, use of a vasopressor agent may be considered although this involves a risk of CNS excitation. Convulsions may be controlled by the intravenous administration of Diazepam or Thiopentone Sodium, bearing in mind that anti-convulsant drugs may also depress respiration and the circulation. Prolonged convulsions may jeopardize the patient’s ventilation and oxygenation and early endotracheal intubation should be considered. If cardiac arrest should occur, standard cardiopulmonary resuscitation procedures should be instituted. Continual optimal oxygenation and ventilation and circulatory support as well as treatment of acidosis are of vital importance.
Dialysis is of negligible value in the treatment of acute overdosage with lidocaine.
- Pharmacological properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Anaesthetics, local, Amides
Lidocaine is used to provide anaesthesia by nerve blockade at various sites in the body and in the control of dysrhythmias. It has a rapid onset of action (about one minute following intravenous injection and fifteen minutes following intramuscular injection) and rapidly spreads through the surrounding tissues. The effect lasts about ten to twenty minutes and about sixty to ninety minutes following intravenous and intramuscular injection respectively.
5.2 Pharmacokinetic properties
The concentration of Lidocaine in the blood will be determined by its rate of absorption from the site of injection, the rate of tissue distribution and the rate of metabolism and excretion.
Absorption
The systemic absorption of Lidocaine is determined by the site of injection, the dosage and its pharmacological profile. The maximum blood concentration occurs following intercostal nerve blockade followed in order of decreasing concentration, the lumbar epidural space, brachial plexus site and subcutaneous tissue. The total dose injected regardless of the site is the primary determinant of the absorption rate and blood levels achieved. There is a linear relationship between the amount of Lidocaine injected and the resultant peak anaesthetic blood levels.
The lipid solubility and vasodilator activity will also influence its rate of absorption. This is seen in the epidural space where Lidocaine is absorbed more rapidly than prilocaine.
Distribution
Lidocaine is distributed throughout the total body water. Its rate of disappearance from the blood can be described by a two or three compartment model. There is a rapid disappearance (alpha) phase which is believed to be related to uptake by rapidly equilibrating tissues (i.e. tissues with a high vascular perfusion). The slower phase is related to distribution, to slowly equilibrating tissues (Betaphase) and to its metabolism and excretion (Gamma phase).
Lidocaine is distributed less rapidly than prilocaine (an amide drug of similar potency and duration of action) but equally as with mepivacaine. Its distribution is throughout all body tissues. In general, the more highly perfused organs will show higher concentrations of Lidocaine. The highest percentage of this drug will be found in skeletal muscle. This is because of the mass of muscle rather than an affinity.
Biotransformation
Lidocaine undergoes enzymatic degradation primarily in the liver. Some degradation may take in tissues other than liver. The main pathway involves oxidative de-ethylation to monoethylglycinexylidide followed by a subsequent hydrolysis to xylidine.
Elimination
The excretion occurs via the kidney with less than 5% in the unchanged form appearing in the urine. The renal clearance is inversely related to its protein binding affinity and the pH of the urine. This suggests by the latter that excretion of Lidocaine occurs by non-ionic diffusion.
5.3 Preclinical safety data
No further relevant information other than that which is included in other sections of the Summary of Product Characteristics.
- Pharmaceutical particulars
6.1 List of excipients
Sodium Chloride
Sodium Hydroxide 10% w/v
Dilute Hydrochloric Acid
Water for Injections
6.2 Incompatibilities
Lidocaine has been found to be incompatible when mixed with amphotericin, methohexitone and glyceryl trinitrate. It is not advisable to mix Lidocaine with other agents.
6.3 Shelf life
4 years (48 months).
If only part of an ampoule is used, the remainder should be discarded.
6.4 Special precautions for storage
Do not store above 25°C.
Keep in outer carton.
6.5 Nature and contents of container
2ml, 5ml, 10ml & 20ml clear One point cut (OPC) glass ampoules, glass type 1 Ph.Eur. presented in cardboard cartons to contain 10 x 2ml ampoules; 10 x 5ml ampoules; 10 x 10ml ampoules and 10 x 20ml ampoules.
6.6 Special precautions for disposal and other handling
For S.C., I.M. or I.V. injection.
Use as directed by the physician.
Keep out of reach of children.
If only part used, discard the remaining solution.
7.Manufactured in India by:
TAJ PHARMACEUTICALS LTD.
Mumbai, India
Unit No. 214.Old Bake House,
Maharashtra chambers of Commerce Lane,
Fort, Mumbai – 400001
at:Gujarat, INDIA.
Customer Service and Product Inquiries:
1-800-TRY-FIRST (1-800-222-434 & 1-800-222-825)
Monday through Saturday 9:00 a.m. to 7:00 p.m. EST
E-mail: tajgroup@tajpharma.com
Lidocaine Hydrochloride 1% w/v Solution for Injection Taj Pharma
Lidocaine Hydrochloride 2% w/v Solution for Injection Taj Pharma
Package leaflet: Information for the patient
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leafleat. See section 4.
The product is referred as above but for ease it has been mentioned as Lidocaine hydrochloride throughout the leaflet.
What is in this leaflet
1. What Lidocaine Hydrochloride is and what it is used for
2. What you need to know before you are given Lidocaine Hydrochloride
3. How Lidocaine Hydrochloride is given to you
4. Possible side effects
5. How to store Lidocaine Hydrochloride
6. Contents of the pack and other information
- What lidocaine hydrochloride is and what it is used for
Lidocaine Hydrochloride is a local anaesthetic and belongs to a class of drugs called amide type local anaesthetics. It produces loss of feeling or sensation confined to one part of the body.
Lidocaine Hydrochloride Injection may be used to produce local numbness (anaesthesia) by injection of the solution into or around the area of operation. It may also be used to produce local anaesthesia by injection of the solution close to the nerves whose conduction is to be cut off, or into the epidural space near the spinal cord, or by administering the solution into a vein in a limb that has been isolated from the circulation by means of a tourniquet (bandage that stops the flow of blood from vessel by applying pressure).
- What you need to know before you are given lidocaine hydrochloride
You should not be given this medicine:
- if you know you are allergic to lidocaine hydrochloride, to any of the other ingredients of this medicine (listed in section 6) or to other similar amide type anaesthetics
- if you suffer from state of decreased blood volume (hypovolaemia)
- if you suffer from abnormality of impulse propagation in the heart causing decreased blood pressure, slow heart rate (complete heart block)
- If the solution also contains adrenaline, lidocaine hydrochloride should not be injected into a vein or used in areas such as fingers, toes, ears, nose or penis, as the blood supply to these areas might become inadequate
Speak to your doctor if one of these applies to you before you are given this medicine.
Warnings and precautions
Talk to your doctor or nurse before you are given Lidocaine Hydrochloride if:
- you suffer from any heart problem, particularly if it affects the heart rate
- you suffer from fits (epilepsy)
- you have low concentration of potassium in the blood causing muscle cramps, constipation (hypokalaemia)
- you ever had an allergic reaction to local anaesthetic e.g. a skin rash or breathlessness or collapse
- you have had recent vomiting, diarrhoea or bleeding, or if you have not been drinking normal amounts of fluid
- you are feeling ill and run down
- you have been told that you have too much acid in your blood and tissues, or not enough oxygen
- you suffer from any liver disease or kidney problems
- you have porphyria (a rare inherited disease that affects the skin and nervous system)
- you have an infection of the skin with pus at or near the site to be injected
- you have problems with your breathing
- you are pregnant, likely to become pregnant or breast-feeding
- you suffer from loss of muscle function and weakness (myasthenia gravis).
Use in children
Lidocaine injection is not recommended for use in neonates (less than a month old).
Other medicines and Lidocaine Hydrochloride
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
A large number of drugs can interact with Lidocaine Hydrochloride which can significantly alter their effects. These drugs include:
- medicines used to treat high blood pressure such as diuretics (water tablets) betablockers, e.g. timolol and propranolol and calcium channel blockers, e.g. verapamil, prenylamine
- medicines used in the treatment of stomach ulcers (e.g. ranitidine, cimetidine)
- dopamine used to stimulate the heart and to treat shock
- strong pain relieving medicines such as codeine and pethidine (Narcotics or opioid drugs)
- medicines used to treat certain types of muscle jerking (e.g. Serotonin or 5- hydroxytryptamine)
- medicines used to treat viral infection (e.g. amprenavir, atazanavir, darunavir and lopinavir)
- medicines used to treat irregular heart beat (mexiletine, amiodarone)
- medicines used to treat infections (quinupristin/dalfopristin)
- medicines used to treat mental disorders (pimozide, sertindole, olanzapine, quetiapine, zotepine)
- medicines used to treat nausea and vomiting (tropisetron, dolasetron).
If adrenaline (epinephrine) is to be added to your lidocaine injection, you should also tell your doctor if you suffer from high blood pressure, shortage of blood supply to the brain, an overactive thyroid gland or if you are taking antidepressant drugs.
If you are already taking one of these medicines, speak to your doctor before you receive Lidocaine Hydrochloride.
Pregnancy and breast-feeding:
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Lidocaine Hydrochloride should only be used during pregnancy and breast feeding if absolutely necessary.
Driving and using machines:
Certain areas of your body will be numb for about 2-4 hours after having this medicine. If this is likely to affect your ability to drive or use machinery you should wait for the effect to wear off.
In general, it is wise to ask your doctor whether it is safe to drive.
Lidocaine Hydrochloride contain sodium
This medicinal product contains less than 1mmol sodium (23mg) per dose, i.e. essentially ‘sodium-free’.
- How lidocaine hydrochloride is given to you
The site of injection will depend on the area to be numbed. It will be administered by a trained healthcare professional. The maximum dose for a healthy adult is 200mg. Your doctor will decide the most suitable dosage for your particular case according to your age and physical circumstances as well as the site of injection, the method used and your response to the injection. If you have any concerns or questions about how much of this medicine you have received, speak to your doctor immediately.
- Possible side effects
Like all medicines, Lidocaine Hydrochloride can cause side effects, although not everyone gets them.
All medicines can cause allergic reactions although serious allergic reactions are rare.
Any sudden wheeziness, difficulty in breathing, swelling of the eyelids, face or lips, rash or itching (especially affecting your whole body) should be reported to a doctor immediately. Lidocaine may result in abnormal amount of methemoglobin (a form of hemoglobin in blood) which may cause bluish discoloration of skin, headache, shortness of breath, malaise and fatigue.
Other serious side effects are also rare, but may occur if too much Lidocaine Hydrochloride is given or if the drug is unintentionally injected into a blood vessel.
Such side effects may occur with certain frequency, which is defined as follows:
Not known: frequency cannot be estimated from the available data
- changes in the rhythm and speed of the heart
- low blood pressure
- slow heart rate (less than 60 beats/minute)
- cessation of normal circulation of blood due to failure of the heart
- pain at the injection site, or numbness or loss of power after the effects of the injection should have worn off
- temporary pain sensation at the lower back, buttocks, legs which resolves within a few days
- numbness or tingling/paralysis of legs after administration of lidocaine in the spine
- difficulty in passing water, problems with the frequency, consistency and/or ability to control your bowel movements (bowel dysfunction)
- loss of balance, pins and needles around the mouth, numbness of the tongue, difficulty tolerating everyday sounds (hyperacusis), ringing in the ears (tinnitus), dizziness or lightheadedness, confusion, nervousness, restless or twitching, changes in your normal mood or behaviour, involuntary rhythmic muscular contractions, fits or seizures, profound state of unconsciousness (coma)
- allergic reaction to local anaesthetic e.g. a skin rash or breathlessness or collapse
- feelings of anxiety or fear
- blurred vision, double vision or transient visual loss
- feeling sick (nausea) or being sick (vomiting)
- breathlessness
- cessation of breathing (respiratory arrest)
- feeling drowsy or faint.
Note : If you are having a blood test, tell your doctor, as injection of lidocaine into a muscle can increase the blood levels of an enzyme marker for muscle damage.
If any of the side effects become serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.
By reporting side effects you can help provide more information on the safety of this medicine.
- How to store lidocaine hydrochloride
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and ampoule label after ‘Exp’. The expiry date refers to the last day of that month.
Do not store above 25°C.
Keep the container in the outer carton in order to protect from light.
The solution should not be used if it is discoloured in any way.
This medicine should not be mixed with any other drugs.
If only part of an ampoule is used, the remaining solution should be discarded.
- Contents of the pack and other information
What Lidocaine Hydrochloride Contains
The active substance is lidocaine hydrochloride.
Lidocaine Hydrochloride Injection 1% w/v, each 1ml of which contains 10mg of active ingredient.
Lidocaine Hydrochloride Injection 2% w/v, each 1ml of which contains 20mg of active ingredient.
The other ingredients are sodium chloride, sodium hydroxide or hydrochloric acid and water for injections.
What Lidocaine Hydrochloride looks like and contents of the pack
Lidocaine Hydrochloride is a clear colourless, sterile solution for injection.
Lidocaine Hydrochloride Injection 1% w/v is available in 2ml, 5ml, 10ml and 20ml clear glass ampoules, packed in boxes of 10 ampoules.
Lidocaine Hydrochloride Injection 2% w/v is available in 2ml, 5ml, 10ml and 20ml clear glass ampoules, packed in boxes of 10 ampoules.
7.Manufactured in India by:
TAJ PHARMACEUTICALS LTD.
Mumbai, India
Unit No. 214.Old Bake House,
Maharashtra chambers of Commerce Lane,
Fort, Mumbai – 400001
at:Gujarat, INDIA.
Customer Service and Product Inquiries:
1-800-TRY-FIRST (1-800-222-434 & 1-800-222-825)
Monday through Saturday 9:00 a.m. to 7:00 p.m. EST
E-mail: tajgroup@tajpharma.com
